Home › Therapeutic areas › Oncology › Ovarian Cancer
Ovarian Cancer (16 companies)
Companies with an active program in Ovarian Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ANIX | Anixa Biosciences | Oncology | 2 | Phase 1 | $111M | 3 |
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $34.5M | 8 |
| CGEN | Compugen | Oncology | 2 | Phase 3 | $186M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $503M | 10 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | $320M | 13 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $88.7M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $3.02B | 14 |
| IMTX | Immatics | Oncology | 1 | Phase 3 | $968M | 8 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.60B | 15 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.13B | 9 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $67.4M | 7 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | $1.70B | 9 |
| VSTM | Verastem | Oncology | 1 | Approved | $1.06B | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.68B | 28 |
| ZNTL | Zentalis Pharmaceuticals | Oncology | 1 | Phase 3 | $123M | 1 |
| ZYME | Zymeworks | OncologyRespiratory | 2 | Approved | $2.10B | 11 |
No companies match.